Drug intelligence / Profile preview

Tears Again liposomal spray

Development stage: Unknown
Lead developer: Optima Pharmazeutische
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical, Ophthalmic

Overview

Tears Again liposomal spray is a CE-marked medical device developed by Optima Pharmaceutical GmbH and distributed by OCuSOFT for the treatment of mild to moderate dry eye disease and Meibomian Gland Dysfunction (MGD). It is a preservative-free phospholipid liposomal formulation containing soy lecithin, Vitamin A palmitate, and Vitamin E. When sprayed onto closed eyelids, the liposomes collect on the lid margins and migrate to the tear film upon blinking. This action stabilizes the tear film lipid layer (TFLL), reducing tear evaporation and improving ocular surface symptoms.

Brand names: Tears AgainTears Again liposomal spray
Other names: Tears Again liposomal eye spray

Beyond the preview

Go deeper on Tears Again liposomal spray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tears Again liposomal spray.

Explore the full profile